<DOC>
	<DOC>NCT01379742</DOC>
	<brief_summary>This study will investigate health related quality of life factors in patients undergoing low dose rate prostate brachytherapy. Patients will be randomized to Iodine-125 Thinstrand (for use with 20 g needles) or Rapidstrand (for use with standard 18 g needles). Urinary, bowel, sexual function and bother will be measured by the EPIC questionnaire at various time intervals.</brief_summary>
	<brief_title>Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirmed adenocarcinoma of the prostate, clinical stage T1c T2b, N0, M0 Greater than or equal to 40 years of age Low and Low Intermediate Risk prostate cancer Prostate volumes by TRUS ≤ 60 cc IPSS score &lt; 25 (alpha blockers allowed) Signed studyspecific informed consent form prior to study entry Lymph node involvement (N1) Evidence of distant metastases (M1) Radical surgery for carcinoma of the prostate Prior pelvic radiation Major medical or psychiatric illness, which in the investigator's opinion would prevent completion of treatment and would interfere with follow up or ability to complete questionnaires Hip prosthesis Inability or refusal to provide informed consent Evidence of Previous TURP Prior hormone therapy Prior TURP</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate brachytherapy</keyword>
</DOC>